Immunotherapy in Some Types of Tumors
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 5
Abstract
Immunotherapy exerts its antitumor action by stimulating the response immune response of patients to cancer, unlike classic treatments, which directly attack the tumor. Previously immunotherapy was limited to patients in whom the conventional treatment, usually with chemotherapy, but currently in patients with some types of tumors, such as melanoma or some lung cancers, is already considered the treatment of first choice. Immunotherapy is able to control some types of malignant tumors prognosis very long, even for several years. Immunotherapy exerts its antitumor action by stimulating the immune response of patients against cancer, unlike classic treatments, which attack directly to the tumor. This implies a series of advantages and characteristics of this novelty strategy. Its main advantage is its ability to control the tumor for very long periods of time in a certain percentage of patients, which varies according to the type of cancer. In some patients with tumors that were previously considered incurable, at this time they are getting very long survivals, even years. Currently, immunotherapy with antibodies that block PD-1 receptors or action on these PD-L1 protein receptors has shown efficacy against a large number of tumors, including among others melanoma, cancers of the lung, kidney, bladder, these treatments are usually administered intravenously and their toxicity is usually lower than conventional treatments, such as chemotherapy.
Authors and Affiliations
Dra Mirta D Ambra
Keywords
Related Articles
- EP ID EP587887
- DOI 10.32474/OAJOM.2018.01.000125
- Views 64
- Downloads 0
Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)
Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second...
A Modern and Comprehensive Experimental Biospectroscopic Comparative Study on Human Common Cancers' Cells, Tissues and Tumors before and after Synchrotron Radiation Therapy
In the current study, we have experimentally and comparatively investigated and compared malignant human common cancers' cells, tissues and tumors such as Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometri...
What is beyond the Nivolumab Monotherapy approval for advanced Hepatocellular Carcinoma?
With an estimated 500,000 new cases per year, hepatocellular carcinoma (HCC) represents the third leading cause of cancer death worldwide. The incidence is rising in the west, largely due to an increasing incidence of he...
Repurposed Drugs and Nutraceutical Supplements as Neglected Complements to Cancer Treatment
In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphat...
Immunotherapy in Some Types of Tumors
Immunotherapy exerts its antitumor action by stimulating the response immune response of patients to cancer, unlike classic treatments, which directly attack the tumor. Previously immunotherapy was limited to patients in...